Every 8-K that Semnur Pharmaceuticals Inc. (SMNRW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SMNRW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMNRW filings page.
Semnur Pharmaceuticals entered into a binding term sheet with iHolding Group LLP for a proposed $100,000,000 equity investment. iHolding is expected to buy newly issued Semnur common shares at $10.00 per share, or about 10,000,000 shares, pending detailed agreements and approvals.
The companies expect proceeds, if the deal closes, to support Semnur’s pipeline, including the ongoing Phase 3 program for SEMDEXA (SP-102), and broader growth initiatives. The transaction is subject to due diligence, definitive agreements, board, stockholder and regulatory approvals, and may not be completed.
Semnur Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 25, 2026. Stockholders representing 5,423,606 shares of Series A preferred stock and 200,307,471 shares of common stock, or about 87% of common shares outstanding as of April 28, 2026, were present virtually or by proxy.
Stockholders elected Jay Chun, M.D., Ph.D. as a Class I director to serve until the 2029 annual meeting. They also ratified Pipara & Co LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved both the 2025 Equity Incentive Plan and the 2025 Employee Stock Purchase Plan.
Semnur Pharmaceuticals, Inc. disclosed that it has terminated two previously agreed equity financing arrangements tied to its deSPAC business combination. Under a Securities Purchase Agreement with JW Capital Securities Limited, Semnur had planned to sell 1,250,000 common shares at $16.00 per share but no shares were ever issued. A separate Securities Purchase Agreement with Biconomy PTE. Ltd. for 6,250,000 common shares at $16.00 per share, payable in Bitcoin, was also terminated. Both agreements were ended effective April 20, 2026, leaving the company without the equity capital those PIPE transactions were intended to provide.
Semnur Pharmaceuticals, Inc. announced that Chief Executive Officer and President Jaisim Shah retired and resigned from his roles and from the board effective March 13, 2026. His departure is stated not to result from any disagreement with the company. Under a separation agreement, he will receive six months of continued base salary at an annual rate of $1,250,000 and a 90‑day extension to exercise vested stock options, and his prior employment agreement was terminated with a general release of claims.
The board reduced its size from six to five directors and appointed Henry Ji, Ph.D. as Chief Executive Officer and President effective at the same time, without changing his compensation. The board also appointed Stephen Ma as Chief Operating Officer effective March 17, 2026, with no change to his compensation, while he continues as Chief Financial Officer and Secretary.
The filing also summarizes related‑party arrangements with controlling stockholder Scilex Holding Company, including a transition services agreement under which Scilex provides various support services with total costs capped at $2.0 million per year for three years, and a $806,366.78 promissory note owed to the SPAC sponsor, payable in six monthly installments and subject to acceleration upon certain equity or debt financings or events of default.
Semnur Pharmaceuticals, Inc. filed a current report to update the official description of its securities. The company’s common stock trades under the symbol SMNR, and its warrants to purchase common stock at an exercise price of $11.50 per share trade under the symbol SMNRW. The updated description reflects amendments to Semnur’s Certificate of Incorporation and Bylaws made since the end of its fiscal year ended December 31, 2024.
The revised Description of Securities is provided as Exhibit 4.1 and replaces any earlier descriptions contained in prior registration statements or reports. It may be incorporated by reference into future Semnur filings under the Securities Act of 1933 and the Securities Exchange Act of 1934, helping keep investors and regulators aligned on the current rights and terms associated with the company’s equity and warrants.